The New York Times Agency May 2010
EN_00914465_2645
(NYT44) SAN FRANCISCO -- June 16, 2004 -- BIOTECH-GROWTH -- John Scarlett, President and CEO of Tercica, left, talks to the company's founder, Prof. Ross Clark, in San Francisco, Calif. on Friday, June 11, 2004. A newly public biotechnology company, Tercica, which uses technology and patents it purchased from Genetech, on Wednesday, June 16, 2004, announced favorable results from a clinical trial of the company's human-growth drug by abnormally short children. The company said that, on average, patients given the drug through twice-a-day injections had grown about an inch more a year than they would have without the treatment. (Dan Krauss/The New York Times)
CENA MINIMALNA - 100 USD
2004-06-16
EAST NEWS
The New York Times Agency
Dan Krauss/The New York Times/Redux
16946245
0,61MB
25cm x 20cm przy 300dpi
11, 16, 2004, A, ABNORMALLY, ABOUT, AN, AND, ANNOUNCED, AVERAGE, BIOTECH-GROWTH, BIOTECHNOLOGY, BY, CALIF, CEO, CHILDREN, CLARK, CLINICAL, COMPANY, DAN, DRUG, FAVORABLE, FOUNDER, FRANCISCO, FRIDAY, FROM, GENETECH, GIVEN, GROWN, HAD, HAVE, HUMAN-GROWTH, IN, INCH, INJECTIONS, IT, JOHN, JUNE, KRAUSS, LEFT, MORE, NEW, NEWLY, NYT44, OF, ON, PATENTS, PATIENTS, PRESIDENT, PROF, PUBLIC, PURCHASED, REDUX, RESULTS, ROSS, SAID, SAN, SCARLETT, SHORT, TALKS, TECHNOLOGY, TERCICA, THAN, THAT, THE, THEY, THROUGH, TIMES, TO, TREATMENT, TRIAL, USES, WEDNESDAY, WHICH, WITHOUT, WOULD, YEAR, YORK,